The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C
ANTIVIRAL THERAPY
Authors: Spaan, Michelle; Bruce, Matthew; Agarwal, Kosh; Carey, Ivana
Abstract
Background: Hepatitis B reactivation in patients with resolved HBV can occur during hepatitis C treatment with direct-acting antivirals, but only a few cases have been described. It is not clear which patients are at risk for HBV reactivation and how to manage them. Methods: Three patients (all hepatitis B surface antigen [HBsAg]-negative, antibody to hepatitis B core (anti-HBc] positive and HBV DNA negative) experienced a late HBV reactivation 12 weeks post-treatment but were able to control their viraemia. HCV RNA, HBV DNA, anti-HBc and anti-HBs were measured in these patients and in 37 HBsAg-negative, anti-HBc positive, HBV DNA negative control patients during direct-acting antiviral therapy for chronic hepatitis C. Results: Baseline anti-HBs do not differ between patients with and without HBV reactivation. Patients with HBV reactivation, however, significantly increased their anti-HBs at time of reactivation, while patients without HBV reactivation show stable anti-HBs during therapy (P=0.007). Conclusions: Anti-HBs might be an important marker to delineate patients at risk for clinically significant HBV reactivation.
Neopterin and soluble CD14 (sCD14) levels as immunoactivation markers in aHBc-only cases
FUTURE VIROLOGY
Authors: Sohrabi, Pari; Habip, Zafer; Saribas, Suat; Vatan, Asli; Dinc, Harika Oyku; Altun, Yagiz M.; Ziver, Tevhide; Caliskan, Reyhan; Demirci, Mehmet; Uysal, Omer; Yuksel, Pelin; Kocazeybek, Bekir
Abstract
Aim: Isolated hepatitis B core antibodies (aHBc)-only pattern complicates the diagnosis of HBV infections. We evaluated neopterin and sCD14 levels in HBV infections. Methods: aHBc-only (n: 102), healthy control (healthy control group [HCG], n: 100), and chronic hepatitis (CHB) groups (n: 70) were investigated. Competitive and sandwich ELISA were used. Results: The mean neopterin levels were significantly lower in the aHBc-only group than those in the CHB group (p = 0.0001). No significant difference was found between the aHBc-only group and the HCG (p = 0.854). The mean sCD14 levels were lower in the aHBc-only group than those in the CHB group (p = 0.0001), but no significant difference was found between the aHBc-only group and HCG (p = 0.402). No significant difference was detected between aHBc-only and HCG for mean sCD14 (p = 0.402) and neopterin levels (p = 0.854). Conclusion: These two biomarkers are not useful for diagnosing the aHBc only pattern.